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的抗肿瘤策略。该策略以截短的组织因子(truncated Tissue Factor, tTF)为效应因





与 tTF 的融合基因，克隆基因至原核表达载体 pET22b(＋)，通过优化其表达条
件，实现目的蛋白在大肠杆菌 BL21(DE3)中的高效表达，用镍亲和层析柱纯化目
的蛋白。凝血实验和 FⅩ活化实验证实两种融合蛋白均保留 tTF 部分活化 FⅩ和
引发血液凝固的的活性。体内实验显示融合蛋白 tTF-EG3287 能有效抑制鼠源性
肝癌 H22 和鼠源性肉瘤 S180 的生长。在 H22 小鼠模型中，tTF-EG3287 的抑瘤
率为 45.08％，在 S180 小鼠模型中，tTF-EG3287 的抑瘤率为 45.78％。组织学观









































tTF-EG3287 和 5FU 联合治疗肿瘤，具有更好的抗肿瘤效果，使为肿瘤血管靶向
治疗提供一种新的治疗方案。 


























Selective thrombosis in tumor vessels and induction of subsequent tumor infarction 
is a promising anti-tumor strategy. This strategy use truncated Tissue Factor (tTF) as 
the effector, tTF(truncated tissue factor) is only the extracellular domain of tissue 
factor. When tTF is targeted to the tumor vasculature by the ligand of tTF fusion 
protein and contacts with the cell membrane closely, it could induce thrombosis in 
tumor vasculature and cut off nutrition and oxygen supplies of tumor, which results in 
necrosis of the tumor and produces anti-tumor effects. 
To test the potential selective thrombosis of tTF fusion protein in tumor vessels, 
Which can be effectively targeted to tumor blood vessels, causing thrombosis. The 
fused genes of tTF with EG3287, were constructed by PCR, and then were inserted 
into vector pET22 b(+), expressed efficiently in E.coli BL21(DE3) under optimization 
condition. The fusion proteins were purified through Nickel-affinity chromatography 
column. The tTF activity of fusion proteins was analyzed by clotting assay and FⅩ
-activation assay. The results indicated that both of them could activiate FⅩ and 
cause blood coagulation. In the H22(mouse liver cancer)-bearing mouse models, the 
tumor growth inhibitions of tTF-EG3287 were 45.08 ％ , respectively. In the 
S180(mouse sarcoma)-bearing mouse models, the tumor growth inhibitions of 
tTF-EG3287 were 45.78％, respectively. In histological studies, the fusion protein 
tTF-EG3287 on Neuropilin-1 has a high affinity, which can be effectively targeted to 
tumor blood vessels, causing thrombosis, causing tumor cell necrosis. No thrombosis 
in blood vessels and cell damage, or other side effects were observed in normal 
tissues. 
Chimeric monoclonal antibody tumor cell nuclear -3/tTF (chTNT-3/tTF) is a novel 
tumor vascular targeting drugs, which can induce large blood clots. chTNT-3 is the Fv 
gene and IgG (1) Fc chimeric gene in the recombinant product, 70% of human parts, 
some 30% of murine. chTNT-3 homology with people no biological limit of the TNT 














with progress, TNT therapeutic advantage is gradually emerging as an integral 
treatment of certain tumors means. The humanized monoclonal antibody tumor cell 
nuclear -3/tTF (huTNT-3/tTF)  will become a new research direction of tumor 
vascular targeting therapy. In vivo experiments showed that the fusion protein 
huTNT-3/tTF can inhibit murine H22 liver cancer and the growth of murine sarcoma 
S180. In the H22(mouse liver cancer)-bearing mouse models, the tumor growth 
inhibitions of huTNT-3/tTF (5μg) was 47.43%, the tumor growth inhibitions of 
huTNT-3/tTF (10μg) was 63.80%, respectively. In the S180(mouse sarcoma)-bearing 
mouse models, the tumor growth inhibitions of huTNT-3 / tTF (5μg, 10μg) were 
53.87%, 61.66%, respectively.  
It was found that huTNT-3/tTF has strong side effects, the current conclusion that 
the dose is better to be administered not more than 10μg of each mice, generally 
between 5-10μg treatment can achieve anti-tumor effect and can reduce mortality. 
huTNT-3/tTF, tTF-EG3287 and 5FU can achieve anti-tumor effect of tumor，which 
caused by different mechanisms of tumor necrosis. In the H22(mouse liver 
cancer)-bearing mouse models, the tumor growth inhibitions of huTNT-3/tTF + 
tTF-EG3287  was 90.42%, the tumor growth inhibitions of huTNT-3/tTF +5 FU was 
86.72%, the tumor growth inhibitions of huTNT-3/tTF +5 FU was 36.94%, 
respectively. In the S180(mouse sarcoma)-bearing mouse models, the tumor growth 
inhibitions of huTNT-3/tTF + tTF-EG3287，huTNT-3/tTF +5 FU ，huTNT-3/tTF +5 
FU were 84.25%, 61.29% and 31.25%, respectively.  huTNT-3/tTF and tTF-EG3287, 
5FU can cause tumor necrosis by different mechanisms. Combination has a 
synergistic effect. 
Based on the above, We constructed， purified and analyzed tTF-EG3287 by 
genetic engineering. We can comparing the anti-tumor effect between different tumors 
in animal models，observing and locating the effect of selective blockage of blood 
vessels induced by tumor and observing the characteristic of tumor necrosis. 
huTNT-3/tTF and tTF-EG3287 can induce thrombosis in tumor vasculature and cut 
off nutrition and oxygen supplies of tumor, which results in necrosis of the tumor and 














produces the better anti-tumor effects. It will become a new treatment of tumor 
vascular targeting therapy. 
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